Table 2.
Effectiveness, cost effectiveness, and outcome information of smoking cessation interventions in the scientific literature (n=6)
| Intervention | Effectiveness | RR (95% CI) | Percentage abstinent, n (%)a | Control group | Outcome measure | CEb |
| Quit Smoking 2.0 [33] | Yes | 2.48 (1.11-5.55) | Int: 224 (8.5), Con: 234 (3.4) | Nontailored email | 7-day point prevalence abstinence at 6 months follow-up | NR |
| SQ4U [34,35] | Yes | AP+: 1.37 (0.97-1.92); AP: 1.49 (1.07-2.06) | Int (AP+): 53 (7.6), Con: 45 (7.1); Int (AP): 63 (9.0), Con: 45 (7.1) | Questionnaires only | Continued abstinence at 12 months follow-up | NR |
| PAS [22,36] | Yes | 1.50 (0.77-2.94) | Int: 20 (15.2); Con: 12 (10.1) | Usual care | Prolonged abstinence at 12-month follow-up | Yes |
| Smoke Alertc [37] | NR | NA | NA | NA | NA | NR |
| STQ [38-41] | Yes | Video: 1.54 (1.08-2.22); text: 1.15 (0.78-1.69) | Int (video): 66 (9.9), Con: 46 (6.4); Int (text): 52 (7.3), Con: 46 (6.2) | Nontailored generic advice | Prolonged abstinence at 12-month follow-up | Yes |
| ABMc [32] | No | NR, for subgroup: 2.33 (1.14-4.76) | Int (subgroup): 22 (14.2); Con: 10 (6.1) | Placebo-training, continued assessments | Continued abstinence at 6 months follow-up | NR |